Synapse - Works

Results (13087)

Glofitamab monotherapy in relapsed or refractory large B-cell lymphoma: Extended follow-up from a pivotal phase II study and subgroup analyses in patients with prior chimeric antigen receptor T-cell therapy and by baseline total metabolic tumor volume

Meeting Abstract

Hutchings, M.; Carlo-Stella, C.; Morschhauser, F.; Falchi, L.; Bachy, E.; Cartron, G.; Khan, C.; Tani, M.; Martinez-Lopez, J.; Bartlett, N. L.; more...
Blood (2023)

Fulltext@MSK | Save

(131)I-apamistamab effectively achieved durable responses in patients with R/R AML irrespective of the presence of multiple high-risk factors

Meeting Abstract

Seropian, S.; Foran, J. M.; Gyurkocza, B.; Nath, R.; Choe, H.; Litzow, M. R.; Koshy, N.; Stiff, P. J.; Tomlinson, B. K.; Abhyankar, S.; more...
Blood (2023)

Fulltext@MSK | Save

Large-scale post-transplant TCR deep sequencing reveals a major T cell diversity bottleneck with post-transplant cyclophosphamide with implications for both efficacy and toxicity: Results of the BMT CTN 1801 study

Meeting Abstract

Kean, L.; Siegel, S. J.; Schmalz, J. T.; Bien, S. A.; Scheffey, D.; Sanders, C.; Robins, H.; Applegate, K.; Bar, M.; Chhabra, S.; more...
Blood (2023)

Fulltext@MSK | Save

Patient-reported outcomes of BMT CTN 1703: A randomized phase III study for GVHD prophylaxis - A quality of life evaluation

Meeting Abstract

Holtan, S. G.; Martens, M. J.; Al Malki, M. M.; Efebera, Y.; Kitko, C. L.; Reshef, R.; Rezvani, A. R.; Shaffer, B. C.; Solh, M. M.; Yao, J. M.; more...
Blood (2023)

Fulltext@MSK | Save

Predictors of cytokine release syndrome and neurotoxicity in patients with large B-cell lymphoma and their impact on survival

Meeting Abstract

Shouval, R.; Strouse, C.; Kim, S.; Oloyede, T.; Ahmed, S.; Awan, F. T.; Bachanova, V.; Badar, T.; Barba, P.; Beitinjaneh, A. M.; more...
Blood (2023)

Fulltext@MSK | Save

ALLO-647 for lymphodepletion in the allogeneic CAR T setting: Safety experience with ALLO-501/501A in patients (pts) with relapsed/refractory (r/r) large B-cell and follicular lymphomas

Meeting Abstract

Locke, F. L.; Munoz, J. L.; Tees, M. T.; Lekakis, L. J.; Eradat, H. A.; de Vos, S.; Nath, R.; Stevens, D. A.; Malik, S. A.; Shouse, G. P.; more...
Blood (2023)

Fulltext@MSK | Save

Real-world evidence in the United States (US) of the impact of bridging therapy prior to axicabtagene ciloleucel (axi-cel) for the treatment of relapsed or refractory large B-cell lymphoma (R/R LBCL)

Meeting Abstract

Cook, M. R.; Shouval, R.; Perales, M. A.; Bezerra, E.; Niu, A.; Dahiya, S.; Nastoupil, L. J.; Jacobson, C. A.; Budde, L. E.; Olson, A. L.; more...
Blood (2023)

Fulltext@MSK | Save

Valemetostat for relapsed or refractory peripheral T-cell lymphomas: Primary results from a phase 1 trial

Meeting Abstract

Jacobsen, E.; Maruyama, D.; Porcu, P.; Tobinai, K.; Allen, P. B.; Ishitsuka, K.; Tsukasaki, K.; Kusumoto, S.; Foss, F. M.; Yamauchi, N.; more...
Blood (2023)

Fulltext@MSK | Save

Asciminib (ASC) in combination with Imatinib (IMA), nilotinib (NIL), or dasatinib (DAS) may be a potential treatment (Tx) option in patients (pts) with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase or accelerated phase (Ph + CML-CP/AP): Final results from the asciminib phase 1 study

Meeting Abstract

Cortes, J.; Lang, F.; Rea, D.; Hochhaus, A.; Breccia, M.; Goh, Y. T.; Heinrich, M. C.; Hughes, T. P.; Janssen, J. J. W. M.; le Coutre, P.; more...
Blood (2023)

Fulltext@MSK | Save

(131)I-apamistamab-led allogeneic hematopoietic cell transplant significantly improves overall survival in patients with TP53 mutated R/R AML

Meeting Abstract

Choe, H.; Tomlinson, B. K.; Gyurkocza, B.; Nath, R.; Seropian, S.; Litzow, M. R.; Abboud, C. N.; Stiff, P. J.; Abhyankar, S.; Foran, J. M.; more...
Blood (2023)

Fulltext@MSK | Save